학술논문

Early antibody treatment, inflammation, and risk of post-COVID conditions.
Document Type
Academic Journal
Author
Gebo KA; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Heath SL; Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham , Birmingham, Alabama, USA.; Fukuta Y; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine , Houston, Texas, USA.; Zhu X; Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Baksh S; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Abraham AG; Department of Epidemiology, University of Colorado, Anschutz Medical Campus , Aurora, Colorado, USA.; Habtehyimer F; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Shade D; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Ruff J; Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Ram M; Departement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Laeyendecker O; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH , Baltimore, Maryland, USA.; Fernandez RE; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Patel EU; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Baker OR; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Shoham S; Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Cachay ER; Department of Medicine, Division of Infectious Diseases, University of California , San Diego, California, USA.; Currier JS; Department of Medicine, Division of Infectious Diseases, University of California , Los Angeles, California, USA.; Gerber JM; Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School , Worchester, Massachusetts, USA.; Meisenberg B; Luminis Health , Annapolis, Maryland, USA.; Forthal DN; Department of Medicine, Division of Infectious Diseases, University of California , Irvine, California, USA.; Hammitt LL; Departement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Huaman MA; Department of Medicine, Division of Infectious Diseases, University of Cincinnati , Cincinnati, Ohio, USA.; Levine A; Department of Emergency Medicine, Rhode Island Hospital Warren Alpert Medical School of Brown University , Providence, Rhode Island, USA.; Mosnaim GS; Department of Medicine, Division of Allergy and Immunology, Northshore University Health System , Evanston, Illinois, USA.; Patel B; Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center , Houston, Texas, USA.; Paxton JH; Department of Emergency Medicine, Wayne State University , Detroit, Michigan, USA.; Raval JS; Department of Pathology, University of New Mexico , Albuquerque, New Mexico, USA.; Sutcliffe CG; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Departement of International Health, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Anjan S; Department of Medicine, Division of Infectious Diseases, University of Miami, Miller School of Medicine , Miami, Florida, USA.; Gniadek T; Department of Pathology, Northshore University Health System , Evanston, Illinois, USA.; Kassaye S; Division of Infectious Diseases, Medstar Georgetown University Hospital , Washington, DC, USA.; Blair JE; Department of Medicine, Division of Infectious Diseases, Mayo Clinic Hospital , Phoenix, Arizona, USA.; Lane K; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; McBee NA; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Gawad AL; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Das P; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Klein SL; Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Pekosz A; Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Bloch EM; Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Hanley D; Department of Neurology, Brain Injury Outcomes Division, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Casadevall A; Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.; Tobian AAR; Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.; Sullivan DJ; Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health , Baltimore, Maryland, USA.
Source
Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 101519231 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2150-7511 (Electronic) NLM ISO Abbreviation: mBio Subsets: MEDLINE
Subject
Language
English
Abstract
Importance: Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.
Competing Interests: See Acknowledgments for conflicts of interest.